CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 308 enrolled
Drug / intervention
Istradefyllinedrug
Likely dose
Istradefylline 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

In the news

12 articles

Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.

Search/NCT00957203
NCT00957203Phase 3Completed
CompareCT.gov

Long-Term Safety Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 3)

Kyowa Kirin Co., Ltd.·interventional·Posted Aug 12, 2009·Updated Aug 31, 2012

In Brief

A Phase 3 clinical trial evaluating Istradefylline for Parkinson's Disease. Completed, enrolled 308 participants across 1 site.

Detailed Summary

Patients with Parkinson's disease who completed the prior double-blind study 6002-009 are eligible to enter into this long-term study. The purpose of this study is to evaluate the safety and efficacy of KW-6002 administered long-term in patients with advanced Parkinson's disease treated with levodopa.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 12, 2009
Enrollment StartOct 1, 2009
Primary CompletionSep 1, 2011
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 16.9 years ago

Interventions

Istradefyllinedrug

Oral istradefylline (KW-6002) 20 or 40 mg once daily